Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.
According to Zacks, “Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (do not eat) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (eat) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. “
Other equities analysts have also recently issued reports about the stock. ValuEngine upgraded shares of Trillium Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. HC Wainwright set a $10.00 target price on shares of Trillium Therapeutics and gave the company a “buy” rating in a research note on Tuesday, April 17th. Finally, Leerink Swann began coverage on shares of Trillium Therapeutics in a research note on Friday, April 13th. They set a “market perform” rating and a $7.00 target price for the company.
Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last released its earnings results on Friday, May 11th. The biotechnology company reported ($0.51) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.64) by $0.13. equities analysts predict that Trillium Therapeutics will post -2.6 earnings per share for the current year.
A number of large investors have recently added to or reduced their stakes in TRIL. Wells Fargo & Company MN raised its stake in Trillium Therapeutics by 57.7% during the 4th quarter. Wells Fargo & Company MN now owns 26,100 shares of the biotechnology company’s stock valued at $189,000 after purchasing an additional 9,550 shares during the last quarter. Stanley Laman Group Ltd. bought a new stake in Trillium Therapeutics in the 1st quarter valued at $779,000. Deutsche Bank AG increased its holdings in Trillium Therapeutics by 1,860.0% in the 4th quarter. Deutsche Bank AG now owns 115,288 shares of the biotechnology company’s stock valued at $835,000 after buying an additional 109,406 shares during the period. Renaissance Technologies LLC bought a new stake in Trillium Therapeutics in the 4th quarter valued at $1,138,000. Finally, Platinum Investment Management Ltd. bought a new stake in Trillium Therapeutics in the 1st quarter valued at $1,255,000. Hedge funds and other institutional investors own 55.56% of the company’s stock.
About Trillium Therapeutics
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies, and solid tumors and mycosis fungoides.
Read More: How to Use the New Google Finance Tool
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.